Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR.
Adult
Aged
Amyotrophic Lateral Sclerosis
/ epidemiology
Case-Control Studies
Cigarette Smoking
Female
Humans
Ireland
/ epidemiology
Italy
/ epidemiology
Male
Middle Aged
Netherlands
/ epidemiology
Risk Assessment
Risk Factors
Smoking
/ adverse effects
Smoking Cessation
Socioeconomic Factors
Young Adult
amyotrophic lateral sclerosis
case–control study
pooled analysis
tobacco
Journal
Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
11
04
2019
revised:
26
06
2019
accepted:
05
08
2019
pubmed:
23
8
2019
medline:
7
7
2020
entrez:
23
8
2019
Statut:
ppublish
Résumé
We investigated the association between cigarette smoking and risk of amyotrophic lateral sclerosis (ALS) in a pooled analysis of population-based case-control studies and explored the independent effects of intensity, duration and time-since-quitting. ALS cases and controls, matched by age, sex and region, were recruited in the Netherlands, Italy and Ireland (*Euro-MOTOR project). Demographics and detailed lifetime smoking histories were collected through questionnaires. Effects of smoking status, intensity (cigarettes/day), duration (years), pack-years and time-since-quitting (years) on ALS risk were estimated using logistic regression models, adjusting for age, sex, alcohol, education and centre. We further investigated effect modification of the linear effects of pack-years by intensity, duration and time-since-quitting using excess OR (eOR) models. Analyses were performed on 1410 cases and 2616 controls. Pack-years were positively associated with ALS risk; OR=1.26 (95% CI: 1.03 to 1.54) for the highest quartile compared with never smokers. This association appeared to be predominantly driven by smoking duration (p Our findings provide further support for the association between smoking and ALS. Pack-years alone may be insufficient to capture effects of different smoking patterns. Time-since-quitting appeared to be an important factor, suggesting that smoking may be an early disease trigger.
Sections du résumé
BACKGROUND
We investigated the association between cigarette smoking and risk of amyotrophic lateral sclerosis (ALS) in a pooled analysis of population-based case-control studies and explored the independent effects of intensity, duration and time-since-quitting.
METHODS
ALS cases and controls, matched by age, sex and region, were recruited in the Netherlands, Italy and Ireland (*Euro-MOTOR project). Demographics and detailed lifetime smoking histories were collected through questionnaires. Effects of smoking status, intensity (cigarettes/day), duration (years), pack-years and time-since-quitting (years) on ALS risk were estimated using logistic regression models, adjusting for age, sex, alcohol, education and centre. We further investigated effect modification of the linear effects of pack-years by intensity, duration and time-since-quitting using excess OR (eOR) models.
RESULTS
Analyses were performed on 1410 cases and 2616 controls. Pack-years were positively associated with ALS risk; OR=1.26 (95% CI: 1.03 to 1.54) for the highest quartile compared with never smokers. This association appeared to be predominantly driven by smoking duration (p
CONCLUSIONS
Our findings provide further support for the association between smoking and ALS. Pack-years alone may be insufficient to capture effects of different smoking patterns. Time-since-quitting appeared to be an important factor, suggesting that smoking may be an early disease trigger.
Identifiants
pubmed: 31434759
pii: jnnp-2019-320986
doi: 10.1136/jnnp-2019-320986
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-39Investigateurs
Anneke J van der Kooi
(AJV)
Joost Raaphorst
(J)
Andrea Calvo
(A)
Cristina Moglia
(C)
Federico Casale
(F)
Giuseppe Fuda
(G)
Antonio Canosa
(A)
Umberto Manera
(U)
Alessandro Bombaci
(A)
Maurizio Grassano
(M)
Rosario Vasta
(R)
Paolina Salamone
(P)
Giuseppe Marrali
(G)
Barbara Iazzolino PsyD
(BI)
Letizia Mazzini
(L)
James Rooney
(J)
Mark Heverin
(M)
Alice Vajda
(A)
Giancarlo Comi
(G)
Nilo Riva
(N)
Francesca Gerardi DrBT
(FG)
Massimiliano Filosto
(M)
Maria Sofia Cotelli
(MS)
Fabrizio Rinaldi
(F)
Luca Chiveri
(L)
Maria Cristina Guaita
(MC)
Patrizia Perrone
(P)
Ceroni Mauro
(C)
Carlo Ferrarese
(C)
Lucio Tremolizzo
(L)
Maria Luisa Delodovici
(ML)
Giorgio Bono
(G)
Rosanna Tortelli
(R)
Card G Panico
(CG)
Chiara Zecca
(C)
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: EB reports grants from UCB-PHARMA, personal fees from MA-Provider, grants from American ALS Association, grants from EISAI, grants from Shire. AC reports personal fees from Biogen, grants from Italfarmaco, personal fees from Roche, personal fees from Cytokinetics, personal fees from Mitsubishi Tanabe. OH has received speaking honoraria from Novartis, Biogen Idec, Sanofi Aventis and Merck-Serono; and has been a member of advisory panels for Biogen Idec, Allergen, Ono Pharmaceuticals, Novartis, Cytokinetics and Sanofi Aventis. LvdB serves on scientific advisory boards for the Prinses Beatrix Spierfonds, Thierry Latran Foundation, Biogen, Cytokinetics, Orion and Sarepta. SP, AEV, FD, JV, LP, GL, EP, JHV and RV report no potential conflicts of interest.